Eisai Inc. Opens Parenteral Facility in Research
Triangle Park
New Global Commercial Manufacturing and Drug Development Site for Eisai’s Intravenous Drug Products
May 19, 2010 04:10 PM Eastern Daylight Time
RESEARCH TRIANGLE PARK, N.C.--(EON: Enhanced Online News)--Eisai Inc., a U.S. subsidiary of Eisai
Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today commemorated the opening of its newly
constructed parenteral facility in Research Triangle Park (RTP), North Carolina. The new site will be utilized for the
commercial production and formulation research and development of intravenous treatments.
The 65,000-square-foot facility will serve as Eisai’s global commercial manufacturing and drug development site for
intravenous drug products in support of the company’s global clinical development programs, including those for
oncology. Eisai invested approximately $100 million in the new facility, which encompasses aseptic processing suites,
laboratories and other support functions. The new operation is designed to handle and process highly potent
compounds utilizing state-of-the-art isolator containment technology.
“Eisai is committed to developing novel anti-cancer agents and other treatments as part of its human health care
(hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide,” said
Haruo Naito, President and CEO, Eisai Co., Ltd. “The opening of this new facility marks a major milestone in our
history and will support the advancement of important new therapies for patients, especially those who are battling
life-threatening illnesses.”
The company has several global drugs in development including compounds being evaluated for breast cancer, lung
cancer, ovarian cancer, and melanoma. Most recently, Eisai submitted simultaneous regulatory applications for
approval of an investigational agent being evaluated as a potential treatment for locally advanced or metastatic breast
cancer, to agencies in Japan, the United